FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, I | D.C. | 20549 |
|---------------|------|-------|
|---------------|------|-------|

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Cardama Alfonso Quintas   |  |       |       |            | 2. Issuer Name and Ticker or Trading Symbol TCR2 THERAPEUTICS INC. [ TCRR ] |   |        |   |          |                       |                       |         |                              |   |                        | all app   | er (give title   | ng Pe                 | erson(s) to Is<br>10% Ov<br>Other (s<br>below)                           | wner  |
|---|--|-------|-------|------------|---|---|--------|---|----------|-----------------------|-----------------------|---------|------------------------------|---|------------------------|---|--|-----------------------|--|---|
| (Last) (First) (Middle)  TCR2 THERAPEUTICS INC.  100 BINNEY STREET  |  |       |       |            |   | 3. Date of Earliest Transaction (Month/Day/Year) 08/31/2020 |        |   |          |                       |                       |         |                              |   |                        | Chief Medic   |  |                       | ,  |   |
| (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)                    |  |       |       |            | 4. If <i>i</i>  | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |        |   |          |                       |                       |         |                              |   | Indivine)              | vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person |  |                       |  |   |
|   |  | Table | 1 - 1 | Non-Deriva | tive  | Secui   | rities | Ac  | quii     | red, D                | isp                   | posed o | f, or I                      | Benefic                                   | ially                  | Own   | ed   |                       |  |   |
| 1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/You |  |       |       |            | ear)   E  | 2A. Deemed<br>Execution Da<br>if any<br>(Month/Day/Y        |        | Co  |          | ransaction Disposed O |                       |         |                              |   | nd 5) Secur<br>Benef   |   | icially<br>d Following   | Fori<br>(D) (<br>Indi | m: Direct<br>or<br>irect (I)   | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|   |  |       |       |            |   |   |        |   | Code     | ·   v                 | Am                    | nount   | (A) or<br>(D)                | Price                                     | Trans                  |   | saction(s)<br>tr. 3 and 4)   |                       | 4)   | (1115411 4)   |
| Common Stock <sup>(1)</sup> 08                                      |  |       |       |            | 20  |   |        |   | A        | V                     | - 1                   | 1,118   | A                            | A \$10.098 <sup>(2</sup>                  |                        | 3,043   |  |                       | D  |   |
| Common Stock <sup>(3)</sup> 02/28/20                                |  |       |       | 02/28/202  | ı   |   |        |   | A        | V                     |                       | 708     | A                            | \$16.124                                  | 16.1245 <sup>(4)</sup> |   | 3,751  |                       | D  |   |
|   | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |       |       |            |   |   |        |   |          |                       |                       |         |                              |   |                        |   |  |                       |  |   |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                 | Derivative Security Conversion Date Security Or Exercise (Month/Day/Year) Execution Date, if any   |       |       |            |   | ansaction code (Instr.   C                                  |        | . Number of derivative decurities acquired A) or disposed of (D) nstr. 3, 4 nd 5) |          | Expiration Date       |                       |         | Amo<br>Secu<br>Unde<br>Deriv | erlying<br>eative<br>rity (Instr.<br>I 4) | Deri<br>Sec            | vative<br>urity<br>tr. 5)   | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(<br>(Instr. 4) | ,                     | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>t (Instr. 4)                           |
|   |  |       |       |            | Code  | Code V (A) (D   |        | (D)   | Da<br>Ex | ate<br>kercisabl      | Expiration<br>le Date |         | Title                        | or<br>Number<br>of<br>Shares              |                        |   |  |                       |  |   |

## **Explanation of Responses:**

- 1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2020 through August 31, 2020. This transaction is exempt under Rule 16b-3(c).
- 2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2020.
- 3. The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP for the ESPP purchase period of September 1, 2020 through February 28, 2021. This transaction is exempt under Rule 16b-3(c).
- 4. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on September 1, 2020.

## Remarks:

/s/ Margaret Siegel as Attorney-in-Fact

03/08/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.